Alzheimer’s disease (AD) is a neurodegenerative disease that is harmful to human health. More and more studies have found that the study of protein characteristics in the peripheral blood of AD patients is helpful for the early diagnosis of AD or Monitor the progress of the disease. The protein in the peripheral protein has the advantages of convenient collection and repeatable detection, so it becomes a candidate biomarker. The detection of biomarkers is essential for the development of drugs for the treatment of Alzheimer’s disease.
In the process of disease occurrence and development, it is often accompanied by changes in the types and quantities of proteins. Proteomics techniques to study the overall characteristics of proteins on a large-scale level can find and identify differential proteins in the blood, thereby screening new biomarkers Things. A type III intermediate fibrin-peripherin widely distributed in the peripheral nervous system (PNS) may be related to neuronal response to injury, nerve regeneration and neuronal deformation. The detection of biomarkers in peripheral blood is of great value for the diagnosis and prediction of AD.
There are many different subtypes of peripheral proteins, and their functions and expression distributions are different. Therefore, the appearance or up-regulation of different subtypes and the changes in the ratio between the subtypes can be signs of different pathological states of the peripheral nervous system (CNS) Or prompt. However, the changes, expression location and specific roles of peripheral protein subtypes in CNS injury are still unclear. At present, many studies on AD peripheral blood biomarkers have confirmed that the pathophysiological process of AD will inevitably produce corresponding changes in peripheral blood. These changes have important guidance and auxiliary effects for the diagnosis and treatment of AD. Biomarkers play an important role in the field of drug research and development, and can be used to diagnose diseases, determine disease stages, or to evaluate the safety and effectiveness of new drugs or new therapies in target populations. Medicilon can provide cytokine and biomarker testing services for medical R&D personnel. Its bioanalysis department has complete infrastructure, advanced equipment and high-end technology platforms such as flow CBA, MSD, and Luminex systems, which can perform various single Detection of multiple forms of cytokines and biomarkers in plex or multiplex.
Recently, a new study published on the preprint website medRxiv stated that researchers from the Flory Institute of Neuroscience and Mental Health and the University of Melbourne’s Alzheimer’s Research Center found that differentially expressed proteins in plasma can act as Alzheimer’s A blood screening tool for Alzheimer’s disease. Peripheral protein signals may help early diagnosis of AD.
The researchers also found a significant correlation between protein levels and APOE genotypes, indicating that differences in genotypes affect the circulating abundance of proteins other than APOE. Researchers in Australia conduct imaging, biomarker and lifestyle related research (AIBL) to help discover three biomarkers. The researchers reported an analysis of the initial plasma samples that were screened from a sex-matched cohort of 72 possible AD patients and 72 healthy controls at the AIBL baseline time point.
Protein is located at the functional end of the central law. It is the executor of biological functions. It can provide the most direct basis for basic medicine, translational medicine and precision medicine. It is a marker that is widely studied and applied. Therefore, the study of protein markers It is also more important. The final study of the study reported significant changes in apolipoprotein E (APOE), haptoglobin, α1-antitrypsin, inter-α trypsin inhibitor, histidine-rich glycoprotein, and proteins with unknown properties. The α1 antitrypsin and α1 antichymotrypsin showed that the plasma concentration was dependent on the APOE eε4 allele dose. The analysis also found that gender is correlated with vitamin D binding protein fragments and complement factor I levels. Then, the researchers used the targeted LC-MS/MS analysis method to validate a single sample. Research results indicate that peripheral proteins may increase the value of plasma amyloid detection for the early diagnosis of AD. Related research will help the development of drugs for the treatment of Alzheimer’s disease.